Search Results - "Bavbek, Sevil E" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

by Grünwald, Viktor, Karakiewicz, Pierre I, Bavbek, Sevil E, Miller, Kurt, Machiels, Jean-Pascal, Lee, Se-Hoon, Larkin, James, Bono, Petri, Rha, Sun Young, Castellano, Daniel, Blank, Christian U, Knox, Jennifer J, Hawkins, Robert, Anak, Oezlem, Rosamilia, Marianne, Booth, Jocelyn, Pirotta, Nicoletta, Bodrogi, István
Published in European journal of cancer (1990) (01.02.2012)

Get full text

Journal Article Web Resource

Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment

Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment

by Argon, Andac, Basaran, Mert, Yaman, Fulya, Dizdar, Yavuz, Sakar, Burak, Camlica, Hakan, Bavbek, Sevil E., Ozger, Harzem, Darendeliler, Emin, Onat, Haluk
Published in Japanese journal of clinical oncology (01.11.2004)

Get full text

Journal Article

Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma

Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma

by Ekenel, Meltem, Keskin, Serkan, Basaran, Mert, Ozdemir, Canan, Meral, Rasim, Altun, Musa, Aslan, Ismet, Bavbek, Sevil E
Published in Oral oncology (01.07.2011)

Get full text

Journal Article

EFFECT OF AGE ON CHARACTERISTICS AND CLINICAL BEHAVIOR OF ADULT AGRESSIVE NON-HODGKIN'S LYMPHOMA

EFFECT OF AGE ON CHARACTERISTICS AND CLINICAL BEHAVIOR OF ADULT AGRESSIVE NON-HODGKIN'S LYMPHOMA

by Suleyman Alici, Sevil E. Bavbek, Mert Basaran, Haluk Onat
Published in Electronic journal of general medicine (26.11.2006)

Get full text

Journal Article

A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults with Nonmetastatic and Extremity Osteosarcomas

A Phase II Study of Cisplatin, Ifosfamide and Epirubicin Combination Chemotherapy in Adults with Nonmetastatic and Extremity Osteosarcomas

by Basaran, Mert, Bavbek, E. Sevil, Saglam, Sezer, Eralp, Levent, Sakar, Burak, Atalar, Ata Can, Bilgic, Bilge, Ozger, Harzem, Onat, Haluk
Published in Oncology (01.01.2007)

Get full text

Journal Article

Timing of death from tumor recurrence after curative gastrectomy for gastric cancer

Timing of death from tumor recurrence after curative gastrectomy for gastric cancer

by Sakar, Burak, Karagol, Hakan, Gumus, Mahmut, Basaran, Mert, Kaytan, Esra, Argon, Andac, Ustuner, Zeki, Bavbek, Sevil E, Bugra, Dursun, Aykan, Faruk N
Published in American journal of clinical oncology (01.04.2004)

Get more information

Journal Article

Prognostic factors in localized aggressive non-Hodgkin's lymphoma

Prognostic factors in localized aggressive non-Hodgkin's lymphoma

by Alici, Süleyman, Bavbek, Sevil E, Kaytan, Esra, Eralp, Yeşim, Onat, Haluk
Published in American journal of clinical oncology (01.02.2003)

Get more information

Journal Article

Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome

Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome

by Altun, Musa, Kaval, Gizem, Ibis, Kamuran, Ozkaya, Kubra, Meral, Rasim, Karadeniz, Ahmet Nafiz, Sari, Murat, Ekenel, Meltem, Basaran, Mert, Bavbek, Sevil E.
Published in Journal of clinical oncology (20.05.2019)

Get full text

Journal Article

Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors

Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors

by Alici, Süleyman, Bavbek, Sevil E, Kaytan, Esra, Başaran, Mert, Eralp, Yeşim, Onat, Haluk
Published in American journal of clinical oncology (01.10.2002)

Get more information

Journal Article

Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?

Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?

by Basaran, Mert, Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Darendeliler, Emin, Bavbek, Sevil E.
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)

Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)

by Tannock, Ian, Fizazi, Karim, Ivanov, Sergey, Thellenberg-Karlsson, Camilla, Flechon, Aude, Skoneczna, Iwona Anna, Orlandi, Francisco Jorquera, Gravis, Gwenaelle, Matveev, Vsevolod, Bavbek, Sevil E., Gil, Thierry, Viana, Luciano S., Aren, Osvaldo, Karyakin, Oleg, Elliott, Tony, Birtle, Alison J., Magherini, Emmanuelle, Petrylak, Daniel Peter, Tombal, Bertrand, Rosenthal, Mark
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)

by Motzer, Robert John, Barrios, Carlos H., Kim, Tae Min, Falcon, Silvia, Cosgriff, Thomas, Harker, W. Graydon, Pittman, Kenneth B., Sabbatini, Roberto, Rha, Sun Young, Flaig, Thomas W., Page, Ray D., Bavbek, Sevil E., Beck, J. Thaddeus, Patel, Poulam M, Schiff, Edward, Vaury, Alexandra, Niolat, Julie, Gogov, Sven, Anak, Ozlem, Knox, Jennifer
Published in Journal of clinical oncology (20.05.2013)

Get full text

Journal Article

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)

by Tannock, Ian, Fizazi, Karim, Ivanov, Sergei, Karlsson, Camilla Thellenberg, Flechon, Aude, Skoneczna, Iwona Anna, Orlandi, Francisco Jorquera, Gravis, Gwenaelle, Matveev, Vsevolod B., Bavbek, Sevil E., Gil, Thierry, Viana, Luciano S., Aren, Osvaldo Rudy, Karyakin, Oleg, Elliott, Tony, Birtle, Alison J., Magherini, Emmanuelle, Hatteville, Laurence, Tombal, Bertrand, Rosenthal, Mark
Published in Journal of clinical oncology (20.02.2013)

Get full text

Journal Article

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results

by Bavbek, Sevil E., Malik, Zafar I, Di Lorenzo, Giuseppe, Scholz, Hans-Jorg, van Oort, Inge M, Ng, Siobhan, Ozguroglu, Mustafa, Gerritsen, Winald R., Mueller, Stefan, Marttila, Timo, Antón Aparicio, Luis M., Albers, Peter, Gschwend, Jürgen E., Bensfia, Samira, Ecstein-Fraïssé, Evelyne B, Bracarda, Sergio, Heidenreich, Axel
Published in Journal of clinical oncology (20.05.2012)

Get full text

Journal Article

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results

by Bavbek, Sevil E., Malik, Zafar, Di Lorenzo, Giuseppe, Scholz, Hans-Jorg, van Oort, Inge M, Ng, Siobhan, Ozguroglu, Mustafa, Gerritsen, Winald R., Mueller, Stefan, Marttila, Timo, Anton-Aparicio, Luis M., Albers, Peter, Gschwend, Juergen, Bensfia, Samira, Ecstein-Fraïssé, Evelyne B, Bracarda, Sergio, Heidenreich, Axel
Published in Journal of clinical oncology (10.02.2012)

Get full text

Journal Article

Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study

Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study

by Basaran, M, Bavbek, E S, Sakar, B, Eralp, Y, Alici, S, Tas, F, Yaman, F, Dogan O, O, Camlica, H, Onat, H
Published in American journal of clinical oncology (01.12.2001)

Get more information

Journal Article

LOW MORTALITY RISK IN THE TREATMENT OF SOLID PATIENTS TUMOR WITH NEUTROPENIA

LOW MORTALITY RISK IN THE TREATMENT OF SOLID PATIENTS TUMOR WITH NEUTROPENIA

by Uygun, Kazim, Başaran, Mert, Yeşi̇m Eralp, Taş, Faruk, Alici, Süleyman, Şakar, Burak, Sevi̇l E Bavbek, Onat, Haluk
Published in Türk onkoloji dergisi (01.01.2000)

Get full text

Journal Article